TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05109806

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: problem prevention therapy with CHD
Description: The psychological exercises are based on the evidence-based Fun FRIENDS protocol (Burhanar, 2016) for reducing emotional behavioral issues. Separate workshop of adolescents will be designed based on transition in child cardiology to adult cardiology(Moons et al., 2009) . A cardiologist and psychologist will psycho educate them about self-care, needs of transition period and strength and strains about further life.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: problem prevention therapy with CHD
Description: The psychological exercises are based on the evidence-based Fun FRIENDS protocol (Burhanar, 2016) for reducing emotional behavioral issues. Separate workshop of adolescents will be designed based on transition in child cardiology to adult cardiology(Moons et al., 2009) . A cardiologist and psychologist will psycho educate them about self-care, needs of transition period and strength and strains about further life.
Study: NCT04896814

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcutaneous tibial nerve stimulation
Description: The participant will be placed in the supine position with the soles of the feet together and the knees flexed and abducted at 90º. Two adhesive electrodes will be used for each leg. First one: 32 mm of diameter that will be placed in the posterior tibial nerve, that is, 4-5 cm cranial to the internal malleolus, between the posterior edge of the medial border of the tibia and the soleus tendon. Second one: 50x50 mm to be placed in the ipsilateral calcaneus. The electrodes will be connected to the NeuroTracTM PelviTone stimulation device. The stimulation range will be selected according to the tolerable pain limit for the patient, between 0.5 and 20 mA (adjustable in 1 mA levels).The intensity elevation will be allowed each time the patient perceives the fading of the previous sensation due to accommodation. Under no circumstances should the stimulation cause a painful feeling.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The participant will be placed in the same position. Two 50 x 50 mm adhesive electrodes will be placed on the external face of the thigh, on a single leg. This area is outside the territory of the posterior tibial nerve. A discontinuous current at 2Hz frequency and a pulsed frequency of 50 µs, with 2 seconds of work and 10 seconds of pause will be applied. This simulated current being considered to be insufficient to achieve therapeutic effects in the body and to be outside of the usual ranges described in electrotherapy manuals regarding pain management. The intensity will be selected according to the paint limit level of the patient, between 0.5 and 60 mA (adjustable in 0.1 mA levels), where a low or moderate sensation of the patient will be sought, without muscle contraction.
Study: NCT04240054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 20 mg PO or IV (10 mg if \>75 years) on days 1, 2, 8, 9, 15, 16, 22 and 23

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 20 mg PO or IV (10 mg if \>75 years) on days 1, 2, 8, 9, 15, 16, 22 and 23
Study: NCT05912348

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Low physical Activity Control
Description: Young men and women will transition into a low physically active lifestyle for 10 days.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Physical Activity and Added Carbohydrate Group
Description: Young men and women will transition into a high physically active lifestyle for 10 days and consume added sugar-sweetened beverages. The intervention group will be compared to two control groups and one experimental group.
Study: NCT01674816

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repeated Measurements of Knee Alignment and Kinematics
Description: Repeated Measurements of Knee Alignment and Kinematics using tools developed by Eiffel Medtech Inc.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Computer Guidance of Surgical Actions
Description: Computer Guidance of Surgical Actions using tools developed by Eiffel Medtech Inc.
Study: NCT06262594

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lemborexant
Description: Drug is administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lemborexant
Description: Drug is administered
Study: NCT05882994

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: rom exercise
Description: At the beginning of the study, participants will be asked to fill out data collection tools consisting of Personal Information Form, Piper Fatigue Scale, Pittsburgh Sleep Quality Index. Data will be collected with data collection tools in the 6th and 12th weeks. Evaluation will be done. At the end of the study, rom exercises will be applied to the patients in the control group.
Study: NCT04729309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [12C] RO7049389
Description: Participants will receive oral \[12C\] RO7049389.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [13C] RO7049389
Description: Participants will receive IV \[13C\] RO7049389.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [13C] RO7049389
Description: Participants will receive IV \[13C\] RO7049389.
Study: NCT06262594

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Drug is administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug is administered
Study: NCT05065268

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immersive Virtual-Reality Stimulation
Description: IVR stimulation every 2 days (± 1 day) at any time during the day (delivery).
Study: NCT05097170

Intervention type: PROCEDURE
Intervention: NIRS during ventricular tachycardia ablation
Description: NIRS: Near-infrared spectroscopy is a measurement technique that non-invasively and continuously monitors the balance between cerebral oxygen consumption and delivery.~BIS: BIS is an electroencephalogram-derived parameter developed to monitor the hypnotic effects of anesthesia.

Intervention type: PROCEDURE
Intervention: NIRS during ventricular tachycardia ablation
Description: NIRS: Near-infrared spectroscopy is a measurement technique that non-invasively and continuously monitors the balance between cerebral oxygen consumption and delivery.~BIS: BIS is an electroencephalogram-derived parameter developed to monitor the hypnotic effects of anesthesia.
Study: NCT05610241

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compression Therapy System Prototype
Description: A device designed to deliver compression therapy at a pre-set level to the lower leg for legs with a circumference between 30-50 cm. The device provides compression through a series of three air bladders and is controlled by a battery-powered electronic module that controls compression levels by monitoring bladder pressure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Compression
Description: Coban 2 represents the standard of care 2-layer compression wrap used to treat venous leg ulcers. The device consists of a comfort layer and a compression layer. A clinician applies the device to establish compression therapy.
Study: NCT05240612

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MT-3921
Description: Solution for infusion; Intravenous (IV)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for infusion; Intravenous (IV)
Study: NCT04729309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] RO7049389
Description: Participants will receive an oral suspension of \[14C\] RO7049389.
Study: NCT05597137

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc Gluconate
Description: Each participant should receive a regular zinc diet for weeks 1-2 and take zinc supplements for weeks 3-4.
Study: NCT05753202

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial current direct stimulation
Description: Transcranial electrical stimulation over two different brain regions associated with cognitive training. 15 sesions in 3 weeks (5 days/week)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial current direct stimulation
Description: Transcranial electrical stimulation over two different brain regions associated with cognitive training. 15 sesions in 3 weeks (5 days/week)
Study: NCT04586075

Intervention type: DIAGNOSTIC_TEST
Intervention: Trio Whole Genome Sequencing and Participant-Specific Research
Description: The initial evaluation begins with short-read genome sequencing of DNA extracted from blood of affected individual(s) and participating family members (The most common approach will be trio whole genome sequencing, which involves the affected child + their parents).~Additional evaluation may include: functional assessments, animal modeling, reverse phenotyping (may require an interim visit), epigenetic profiling, or clinical database matching through selective sharing of coded patient data with external collaborators (e.g., via Matchmaker Exchange and Phenome Central), long read genome sequencing, de novo genome assembly, RNA sequencing, and novel bioinformatics analyses
Study: NCT04809025

Intervention type: DEVICE
Intervention: endoscopy
Description: gastroscope

Intervention type: PROCEDURE
Intervention: Surgery
Description: radical gastrectomy
Study: NCT06181227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVD-104
Description: An intravitreal injection of 50 microliters at the doses described will be given. Visual acuity, optical coherence tomography thickness and vascular perfusion will be evaluated for an effect of the drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVD-104
Description: An intravitreal injection of 50 microliters at the doses described will be given. Visual acuity, optical coherence tomography thickness and vascular perfusion will be evaluated for an effect of the drug.
Study: NCT05108441

Intervention type: OTHER
Group type: OTHER
Intervention: Ultrasound and magnetic resonance imaging measurements of quadriceps femoris
Description: In sedated critically ill children, quadriceps femoris thickness and cross sectional area will be measured with thigh bedside ultrasound, performed by two trained operators consecutively. These two measurements will also be made at the exact same location on a magnetic resonance imaging transverse view of the thigh, to allow comparing them to ultrasound measurements.
Study: NCT05757024

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high power laser therapy
Description: m6 laser therapy of ASA company with multilocked wave system and synchronized emission wave lengths 808 and 905 wave lengths

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high power laser therapy
Description: m6 laser therapy of ASA company with multilocked wave system and synchronized emission wave lengths 808 and 905 wave lengths
Study: NCT05287204

Intervention type: DIAGNOSTIC_TEST
Intervention: Musculoskeletal ultrasound
Description: Ultrasound of rectus femoris to determine cross-sectional area, muscle thickness, echo intensity.

Intervention type: DIAGNOSTIC_TEST
Intervention: Musculoskeletal ultrasound
Description: Ultrasound of rectus femoris to determine cross-sectional area, muscle thickness, echo intensity.

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessments of muscle strength and physical function
Description: A battery of tests of physical function and muscle strength (see outcomes section for details).

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessments of muscle strength and physical function
Description: A battery of tests of physical function and muscle strength (see outcomes section for details).

Intervention type: DIAGNOSTIC_TEST
Intervention: Metabolomics
Description: Using metabolomic analysis, concentrations of amino acids and other important analytes will be measured in patient plasma and CRRT effluent
Study: NCT06039150

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: M-TAPA Block
Description: M-TAPA Block; The block will be done by the same experienced anesthesiologist by using ultrasound(USG) after the surgical intervention is completed.The external oblique, internal oblique, and transversus abdominis muscles were shown on the costochondral angle in the sagittal plane at the 10th costal margin by using a high-frequency linear probe. Bilaterally in the midclavicular line at the level of the 10th rib (arcus costarum),0,5 ml/kg 0.25% Bupivacaine (maximum dose 2mg/kg) was administered to between the upper fascia of the transversus abdominis muscle and the lower fascia of the costochondral tissue.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthetic infltration to port sites
Description: Local anesthetic infiltration to port sites; The surgeon infiltrated 0.5 ml/kg of 0.25% Bupivacaine (maximum dose of 2mg/kg) in the skin, subcutaneous tissue, and muscle fascia at each of the three laparoscopic port areas at the end of the surgery.
Study: NCT05904314

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simulation training in electronic fetal monitor management
Description: Simulation training in electronic fetal monitor management
Study: NCT06245824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd) with pyrotinib
Description: T-DXd, 5.4mg/kg IV day 1 of a 21-day cycle. Pyrotinib, 400mg or 320mg, orally once a day, daily of a 21-day cycle.
Study: NCT04897594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TERN-201
Description: Investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TERN-201
Description: Investigational drug
Study: NCT05935111

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity Self-efficacy (PAS) intervention
Description: The PAS intervention will be a web-based intervention to address the unique barriers to physical activity in adults with obesity, based on self-efficacy theory and effective behavioral change techniques. Self-efficacy is specified as a mediating psychological variable in the conceptual model for the promotion of physical activity. Self-efficacy refers to domain-specific beliefs (e.g., job-, transport-, domestic-, leisure-related physical activity) about their ability to execute differing levels of performance given situational demands. There is a rich literature on the importance of targeting self-efficacy as a modifiable mediating variable in PA-promoting interventions. Also, the PAS intervention will consist of effective behavioral change techniques (e.g., action planning, teach to use prompts/cues, goal setting, etc.).
Study: NCT04730349

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NKTR-214
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NKTR-214
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NKTR-214
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NKTR-214
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NKTR-214
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NKTR-214
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NKTR-214
Description: Specified dose on specified days
Study: NCT05055362

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Honey Spice Group
Description: Consume baked good daily for 10 days and provide samples of saliva, urine and dietary habits and spice intake.
Study: NCT04730349

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NKTR-214
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NKTR-214
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NKTR-214
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NKTR-214
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NKTR-214
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NKTR-214
Description: Specified dose on specified days
Study: NCT05872893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Patients will receive age-adjusted doses of ondansetron 5mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Patients will receive age-adjusted doses of ondansetron 5mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Patients will receive dexamethasone 4mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Patients will receive dexamethasone 4mg/m2
Study: NCT05145179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSGJ-705
Description: 0.1, 1, 3, 6, 10, 15 or 20mg/kg, IV, Day 1, 8, 15 of each treatment cycle, up to disease progression or intolerable toxicity, death, early withdrawal from the study or loss to follow-up, withdrawal of consent, or the end of the treatment period, whichever occurs first. Every 4 weeks a treatment cycle.
Study: NCT04897594

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT04901104

Intervention type: DRUG
Intervention: Thymosin Alpha1
Description: Drug interventions have been done in previous clinical studies
Study: NCT02324712

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture using standard stainless steel acupuncture needles inserted into intramuscular tissue for 20 minutes

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: Acupuncture using non-penetrating Park Sham Needles for 20 minutes
Study: NCT06454162

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Ketogenic Diet
Description: the patients will receive KD after nutritional counseling, patients will instructed to start by limiting carbohydrate intake to just 20 g/day for 4 weeks in order to establish ketosis. Then, patients increase their carbohydrate intake by 5 g each week until they reach their individual maximum (approximately 40 g) to maintain stable ketosis. All carbohydrates relevant for elevating blood glucose are limited to 40-50 g/ day. In addition, the glycemic index and glycemic load of carbohydrates have to be below 50 and 60, respectively. This ketogenic diet is equivalent to a traditional ketogenic diet, but with a liberalized macronutrient composition of 70-80% fats, 15-20% proteins and 5-10% carbohydrates (compared to a traditional ketogenic diet with 90% fat, 6% proteins and 4% carbohydrates)+ exercise program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise program
Description: the patients will receive exercise program in the form of aerobic training (10-30 minutes at moderate intensity) and resistance training (1-3 sets of 8-15 repetition maximum (RM)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise program
Description: the patients will receive exercise program in the form of aerobic training (10-30 minutes at moderate intensity) and resistance training (1-3 sets of 8-15 repetition maximum (RM)
Study: NCT05038787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3473329
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study: NCT06360497

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mindfulness meditation intervention and loving-kindness and compassion meditation intervention
Description: Interventions were conducted by two teachers separately. Mindfulness meditation group provided the knowledge and practice related with mindfulness, and loving-kindness and compassion meditation group provided knowledge and practice related with loving-kindness and compassion meditation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mindfulness meditation intervention and loving-kindness and compassion meditation intervention
Description: Interventions were conducted by two teachers separately. Mindfulness meditation group provided the knowledge and practice related with mindfulness, and loving-kindness and compassion meditation group provided knowledge and practice related with loving-kindness and compassion meditation.
Study: NCT05045105

Intervention type: OTHER
Intervention: Time necessary for ICP catheter placement by Intensive Care Physician vs Neurosurgeon following indication
Description: Time necessary for ICP catheter placement by Intensive Care Physician vs Neurosurgeon following indication and complications related to the maneuver between the two cohorts will be evaluated and compared.

Intervention type: OTHER
Intervention: Time necessary for ICP catheter placement by Intensive Care Physician vs Neurosurgeon following indication
Description: Time necessary for ICP catheter placement by Intensive Care Physician vs Neurosurgeon following indication and complications related to the maneuver between the two cohorts will be evaluated and compared.